Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: Tissue microarray assay in resected lung cancer specimens

Annals of Diagnostic Pathology

Volumn 17, Issue 1, 2013, Pages 85-90

  Kim, Mi Jin ^a   Shin, Hyeong Chan ^a   Shin, Kyeong Cheol ^a   Ro, Jae Y ^b  

^a Yeungnam University College of Medicine   (South Korea)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

Adenocarcinoma; Immunohistochemistry; Non small cell lung carcinoma; Squamous cell carcinoma

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOOXYGENASE 2; CYTOKERATIN 5; CYTOKERATIN 6; PROTEIN NAPSIN A; PROTEIN P63; RETINOBLASTOMA PROTEIN; THROMBOMODULIN; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURGERY; COLON METASTASIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; APOPTOSIS REGULATORY PROTEINS; ASPARTIC ACID ENDOPEPTIDASES; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; LUNG; LUNG NEOPLASMS; NUCLEAR PROTEINS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84870567028     PISSN: 10929134     EISSN: 15328198     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2012.07.006     Document Type: Article

References (30)

1. W.D. Travis Pathology of lung cancer Clin Chest Med 23 2002 65 81
2. M. Parkin, J.E. Tyezynski, and P. Boffetta Lung cancer epidemiology and etiology W.D. Travis, lung, pleura, thymus and heart 2004 IARC Press Lyon, France 12 15
3. A. Jemal, M.J. Thun, and L.A.G. Ries Annual report the nation on the status of cancer. 1975-2005 featuring lung cancer, tobacco use and tobacco control JNCI 100 2008 1672 1694
4. T. Ueno, S. Linder, and G. Elmberger Aspartic proteinase napsin is useful marker for diagnosis of primary lung adenocarcinoma Br J Cancer 88 2003 1229 1233
5. V. Miller, M. Dris, and N. Shah Bronchioloalveolar pathologic subtype and smoking history predict sensitivity of gefitinib in advanced non-small cell lung cancer J Clin Oncol 22 2004 1103 1109
6. K. Inamura, H. Ninomiya, and Y. Ishikawa Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med 134 2010 66 72
7. D.F. Johnson, L. Fehrenbacher, and W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall cell lung cancer J Clin Oncol 22 2004 2184 2191
8. M.H. Cohen, J. Gootenberg, P. Keegan, and R. Pazdur FDA drug approval summary: Bevacizumab (Avastin) plus carboplatin and paclitaxel as first- treatment of advanced/metastatic recurrent non squamous non-small cell lung cancer Oncologist 12 2007 713 718
9. J. Carlson Erlotinib in non-small cell cancer: a review of the clinical and economic evidence Exp Rev Phamacoecon Outcomes Res. 9 2009 409 416
10. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinomas N Engl J Med 361 2009 947 957
11. G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with stage in non-small cell lung cancer J Clin Oncol 26 2008 3543 3548
12. S. Khayyata, S. Yun, and T. Pasha Value of p63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens Diag Cytopathol 37 2009 178 183
13. E. Conde, B. Angulo, and P. Redondo The use of p63 immunohistochemistry for the identification of squamous cell carcinoma of the lung PLoS One 5 2010 1 6
14. N. Fatima, C. Cohen, and D. Lawson TTF1 and napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks Cancer Cytopathol 25 2011 127 133
15. P.G. Chu, and L.M. Weiss Expression of cytokeratin 5/6 immunostaining in epithelial neoplasm: an immunohistochemical study of 509 cases Mod Pathol 15 2003 6 10
16. F.R. Hirsch, A. Spreafico, and S. Novello The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review J Thorac Oncol 3 2008 1468 1481
17. J. Terry, and S. Leung Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples Am J Surg Pathol 34 2010 1805 1811
18. P.S. Loo, S.C. Thomas, and M.C. Nicolson Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens J Thorac Oncol 5 2010 442 447
19. S. Mukhopadhyay, and A.L. Katzenstein Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimen: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6 Am J Surg Pathol 35 2011 15 25
20. P. Downey, R. Cummins, and M. Morn If it's not CK5/6 positive, TTF-1 negative it's not a squamous cell carcinoma of lung APMIS 116 2008 526 529
21. L. Johansson Histopathologic classification of lung cancer: relevance of cytokeratin and TTF-1 immunophenotyping Ann Diagn Pathol 8 2004 259 267
22. N. Nakamura, E. Miyagi, and S. Murata Expression of thyroid transcription facroe-1 in normal and neoplastic lung tissues Mod Pathol 22 2009 709 717
23. T. Hirano, G. Auer, and M. Maeda Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A Jpn J Cancer Res 91 2000 1015 1021
24. L.M. Stoll, M.W. Johnson, and E. Gabrielson The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas Cancer Cytopathol 25 2010 441 449
25. J.A. Bishop, R. Sharma, and P.B. Illei Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma Hum Pathol 41 2010 20 25
26. B.M. Turner, P.T. Cagle, and I.M. Sainz Napsin A, new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma Arch Pathol Lab Med 136 2012 163 282
27. R.T. Pu, Y. Pang, and C.W. Michael Utility of WT-1, p63. MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in infusion Diagn Cytopathol 36 2007 20 25
28. M. Miettinen, and M. Sarlomo-Rikala Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura Am J Surg Pathol 27 2003 150 158
29. L. Viberti, M. Bongiovanni, and S. Croce 34βE12 cytokeratin immunodetection in the differential diagnosis of small cell tumors of lung Int J Surg Pathol 8 2000 317 322
30. Y. Yatanabe, A. Masuda, and T. Koshika p27kip1 in human lung cancers: differential changes in small cell and non-small cell carcinomas Cancer Res 58 1998 1042 1047